Vertical cup‐disc ratio: the proportion of participants with asymmetrical vertical cup‐disc ratio greater than 0.3 at 4 years' · people with open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: ocular allergy to the study medication requiring discontinuation up to 4 years' · people with open‐angle glaucoma
It is very uncertain whether neuroprotection changes adverse effects: ocular allergy to the study medication requiring… compared with control (very low certainty).
1 finding from 1 review
Quality of life measures · people with open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost / economic data · people with open‐angle glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with 'any bleeding' event(s) (WHO grade 1 to 4 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets may leads to higher number of participants with 'any bleeding' event(s) (WHO grade 1 to… compared with standard platelets (low certainty).
1 finding from 1 review
Number of participants with clinically significant bleeding · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'clinically significant' bleeding… compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with 'severe' bleeding event(s) (WHO grade ≥ 3 or equivalent) ‐ · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with 'severe' bleeding event(s) (WHO grade ≥… compared with standard platelets (moderate certainty).
1 finding from 1 review
All‐cause mortality · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants with a serious adverse event · thrombocytopenia
Pathogen‐reduced platelets showed no clear difference in number of participants with a serious adverse event compared with standard platelets (moderate certainty).
1 finding from 1 review
Number of participants experiencing platelet refractoriness · thrombocytopenia
Pathogen‐reduced platelets leads to higher number of participants experiencing platelet refractoriness compared with standard platelets (high certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · thrombocytopenia
1 finding from 1 review
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for rapid tranquillisation ‐ more than 3 injections · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more than 3 injections compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tremor · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ tremor by 7 days compared with OTHER ANTIPSYCHOTIC: k. ZUCLOPENTHIXOL ACETATE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · Adult patients with myelodysplastic syndromes and thrombocytopenia
1 finding from 1 review
Mortality during study · Adult patients with myelodysplastic syndromes and thrombocytopenia
Thrombopoietin mimetics showed no clear difference in mortality during study compared with placebo (low certainty).
1 finding from 1 review
Transformation to AML · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes transformation to AML compared with placebo (very low certainty).
1 finding from 1 review